Worth Watching Active Stock’s News Update: Facebook Inc (NASDAQ:FB), Infoblox Inc (NYSE:BLOX), Johnson & Johnson (NYSE:JNJ)

On Monday, Shares of Facebook Inc (NASDAQ:FB), added 0.39% and closed at $128.77 in the last trading session. The last trading range of the stock ranges between $127.80 and $129.09. Facebook, Inc. (FB) declared recently that the company’s third quarter 2016 financial results will be released after market close on Wednesday, November 2, 2016.

Founded in 2004, Facebook’s mission is to give people the power to share and make the world more open and connected. People use Facebook to stay connected with friends and family, to discover what’s going on in the world, and to share and express what matters to them.

Infoblox Inc (NYSE:BLOX), DROPPED -0.34% and closed at $26.27 in the last trading session. The last trading range of the stock ranges between $26.27 and $26.39. The company’s Market capitalization is $1.46 Billion with the total Outstanding Shares of 55.60 Million. Infoblox Inc., together with its auxiliaries, designs, develops, manufactures, and sells network control solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Trinzic DDI, an appliance designed to ensure the continuous secure operation of network services; Network Insight, a tool that delivers automated discovery, and switch port inventory and control; and IPAM for Microsoft, a Web-based administration interface for the centralized administration of Microsoft domain name system (DNS), dynamic host configuration protocol (DHCP), and multiple IP address pools. It also provides Trinzic Reporting that automates time-consuming manual tasks associated with collecting, tabulating, and correlating data through its single point of control; DNS Traffic Control solution; External DNS Security, an appliance designed to protect the customer network from cyber-attacks by using threat intelligence; and Internal DNS Security provides security functionality to internal DNS servers. In addition, the company offers DNS Firewall that assists organizations to detect and protect from malware and advanced persistent threats; Infoblox DDI for Amazon Web Services, which provides DNS and DHCP functionality to the Amazon Web Services cloud networking environment; NetMRI that automates network change and configuration administration processes; and Automation Change Manager that automates network configuration functions for end customers to make network changes without manual intervention and in real-time.

Johnson & Johnson (NYSE:JNJ), gained 0.58% and closed at $118.81 in the last trading session. The last trading range of the stock ranges between $117.43 and $119.01. During the 52-week trading session the minimum price at which share price traded, registered at $91.84 and reached to max level of $126.07. Johnson & Johnson, together with its auxiliaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON’S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women’s health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, counting adhesive bandages under the BAND-AID brand name and first aid products under the NEOSPORIN brand name. This segment also provides over-the-counter medicines, counting acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases.

Leave a Reply

Your email address will not be published. Required fields are marked *